RYTM - Rhythm Pharma gets orphan status for setmelanotide September, 19 2019 06:41 PM Rhythm Pharmaceuticals Inc. Rhythm Pharmaceuticals (NASDAQ:RYTM) has been granted orphan drug designation for setmelanotide in treatment of Bardet-Biedl syndrome.More news on: Rhythm Pharmaceuticals, Inc., Healthcare stocks news, Read more ...